Alesi Surgical has raised £7 million in a funding round led by IW Capital, with participation from existing investors IP Group and Mercia Ventures.
The company develops surgical smoke management technology aimed at improving visibility and safety in operating theatres, addressing a long-standing but often overlooked issue in surgical environments worldwide.
What The Company Does
Alesi Surgical develops technologies designed to reduce and manage surgical smoke generated during electrosurgical procedures. This smoke, produced in the majority of operations globally, can reduce visibility for surgeons and expose medical staff and patients to potentially harmful particles such as bacteria, viruses, and chemical compounds.
The company’s core product, the Ultravision platform, uses electrostatic precipitation to capture smoke directly at the source rather than relying on traditional suction-based systems. This approach is designed to provide more consistent smoke removal without interfering with surgical workflows.
Its first-generation system has been deployed in over 50,000 laparoscopic and robotic procedures across Europe, the United States, and Japan, where it has demonstrated faster smoke clearance compared to conventional technologies.
The platform also enables procedures to be conducted at lower abdominal pressure, reducing CO₂ usage and improving clinical outcomes such as recovery time and procedural efficiency.
The next-generation Ultravision2 system extends these capabilities to open surgery and integrates directly with advanced surgical tools, combining smoke management with surgical instrumentation in a more unified setup.
Advertisement
Market Context / Industry Background
Surgical smoke management has become an increasing focus in healthcare as awareness grows around occupational exposure risks and operating theatre safety standards. Despite the widespread use of electrosurgical tools, adoption of dedicated smoke evacuation systems has historically been limited.
One of the main barriers has been the design of traditional systems, which are often bulky and disruptive to surgical workflows. This has slowed integration into routine practice, even as evidence of health and operational impacts has accumulated.
Regulatory and institutional pressure is now increasing globally, with healthcare systems placing greater emphasis on safer operating environments and improved surgical efficiency. This is driving demand for solutions that can integrate seamlessly into existing procedures without compromising performance.
Founder / Investor Commentary
Dr Dominic Griffiths, Founder and CEO of Alesi Surgical, noted that while electrosurgical tools have significantly advanced modern surgery, they also produce smoke that can impair visibility, reduce efficiency, and pose health risks to operating theatre staff.
He highlighted that previous solutions have often required trade-offs between effectiveness and disruption to surgical workflows, which has limited adoption across the industry. Griffiths added that growing recognition of smoke management as a core component of surgical safety is accelerating interest in technologies that address the issue at its source, including the FDA-approved and CE-marked Ultravision2 system.
Isobel Egemole, Investment Director at IW Capital, said the company offers a fundamentally different approach by targeting the root cause of surgical smoke. She noted that as smoke-free operating theatres become a broader industry standard, Ultravision2 is positioned to play an important role in this transition.
Growth Plans / Use Of Funds
The new capital will support Alesi Surgical’s international expansion and further development of its Ultravision2 platform. The company is also expected to continue working on regulatory adoption and integration across different surgical environments, particularly as demand increases for safer and more efficient operating theatre technologies.
About Alesi Surgical
Alesi Surgical is a medical technology company founded in 2009 that develops solutions to improve the safety and efficiency of surgical procedures. Spun out from WIMAT, the company focuses on surgical smoke management and electrosurgical innovation. Its FDA-cleared Ultravision2 system combines advanced smoke control with surgical tools to enhance visibility, improve outcomes, and support safer operating theatre environments.
